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doi:10.1016/j.ejvs.2009.02.005Abstract Objectives: The aim of this study was to evaluate the safety of selective and sus-
tained delivery of basic fibroblast growth factor (bFGF) using acidic gelatine hydrogel micro-
spheres (AGHMs) for the treatment of peripheral arterial disease (PAD).
Materials and methods: We conducted a non-randomised and uncontrolled trial involving
prospective observation of eight patients (eight limbs) with PADd five limbs with arterioscle-
rosis obliterans and three limbs with thromboangiitis obliterans, five limbs (three arms and two
legs) with critical limb ischaemia (CLI) and three limbs with intermittent claudication (IC)
d who were followed up for 6 months or more. AGHM suspension containing 100 mg bFGF
was infused into the artery of the affected limb. Besides evaluation of safety and changes
in symptoms, resting ankleebrachial pressure index measurement and transcutaneous PO2
(tcPO2), angiography were conducted at baseline and then at various time points. Skin perfu-
sion pressure as an index of CLI and claudication distance as an index of IC were also used to
assess clinical improvement and limb perfusion.
Results: No serious adverse events were observed. All cases showed improvement in symp-
toms, although this was temporary in some patients.
Conclusion: Selective delivery of bFGF using AGHMs was suggested to be safe and well-toler-
ated in patients with PAD.
Crown Copyright ª 2009 Published by Elsevier Ltd on behalf of European Society for Vascular
Surgery. All rights reserved.3811 6822; fax: þ81 3 5800
kyo.ac.jp (T. Miyata).
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72 T. Hashimoto et al.ischaemic tissue. It is widely accepted that remodelling of
pre-existing interarterial connections by arteriogenesis
(maturation and enlargement of immature arteries) plays
an essential role in collateral development.1e4 Therefore,
a reasonable strategy for therapeutic angiogenesis is to
induce enhancement of arteriogenesis to form connections
between a non-occluded artery with sufficient blood inflow
(the donor artery) and the ischaemic tissue, and expect
them to become functional collateral vessels.
Basic fibroblast growth factor (bFGF) is a protein that
causes a harmonised arteriogenic effect inducing several
downstream signals such as vascular endothelial growth
factor (VEGF) and monocyte chemoattractant protein-1
(MCP-1).5-8
However, recombinant bFGF has shown only limited
efficacy in randomised clinical trials.9,10 Part of this failure is
attributable to suboptimal delivery strategies for growth
factors, as a result of their low accumulation in ischaemic
tissue and their rapid inactivation.11 We designed a method
of site-specific sustained delivery of bFGF using acidic
gelatine hydrogel microspheres (AGHMs) that, when admin-
istered into the donor artery, become trapped in small
arterioles that connect the donor artery and the ischaemic
tissue.11 Administration of 29-mm AGHMs, designed to
continuously deliver bFGF for 14 days, induced marked
collateral vessel development in a pre-clinical study.11
The aim of this trial was to evaluate the safety of this
novel delivery system for bFGF in patients with PAD (Fig. 1).Materials and Methods
Between 2004 and 2008, we conducted a non-randomised
and uncontrolled trial involving prospective observation of
PAD patients, followed up for 6months ormore. The subjects
were patients with critical limb ischaemia (CLI) due to
arteriosclerosis obliterans (ASO) or thromboangiitis obliter-
ans (TAO) who were not candidates for arterialFigure 1 Selective delivery of bFGF using acidic gelatine hydro
circles) are injected via the donor artery. Based on our pre-clinical
of the donor artery (target of delivery) and continuously release breconstruction, and patients with intermittent claudication
(IC) due to infra-inguinal ASO. They were required to be on
a stable medication regimen for six weeks before entry.
Smoking cessation was urged for all eligible patients.
Excluded from this trial were patients with malignancy
within the past 5 years, severe proliferative diabetic reti-
nopathy, or any intervention including re-vascularisation
within the past 2 months. Nine limbs of eight PAD patients
were originally enrolled. However, one patient withdrew in
his second enrollment in the study, leaving eight limbs in
eight patients (five limbs with ASO and three limbs with TAO;
four limbs with ulcer or necrosis, one limbwith rest pain, and
three limbs with IC; six men and two women aged 37e84
years, mean 61.5 17.9 years). The study was approved by
the medical ethics committee of the University of Tokyo
Hospital.
AGHMswith amean diameter of 29 mmwereprepared from
gelatine (Nitta Gelatin) as described previously, in the cell
processing centre at our institute.12,13 100 mg human
recombinant bFGF (trafermin, Kaken Pharmaceutical) in
50 mL distilled water was absorbed into 3 mg freeze-dried
AGHMs.
Under local anaesthesia, the femoral or brachial artery
was punctured and a 4 Fr sheath was inserted in a down-
ward direction. Then, bFGF-impregnated AGHMs suspended
in 10 mL normal saline were infused into the donor artery of
the affected limb via a straight catheter.
For safety evaluation, blood pressure was monitored for
30 min after treatment to detect a possible acute hypoten-
sive effect of bFGF. Liver enzymes, creatine kinase, lactate
dehydrogenase measurement and urinalysis were performed
at 1, 3 and 7 days after treatment to detect possible liver
toxicity, emboli and renal dysfunction. Serum bFGF concen-
tration wasmeasured by ELISA immediately after treatment;
1 day; 1, 2 and3weeks and1, 3 and6months after treatment.
Detailed safety information including retinal photographic
images and tumour markers were obtained through 1 year.gel microspheres (AGHMs). bFGF-impregnated AGHMs (yellow
results, AGHMs are expected to be trapped in the distal portion
FGF for 2 weeks.
Table 1 Clinical and laboratory findings before and 6 months after intra-arterial administration of bFGF-impregnated AGHMs
Case Age, Sex Study
Type
Vascular
Disease
Affected
Limb
Signs and
Symptoms
Changes in Signs and Symptoms Pressure
Indexc
tcPO2/
Control
SPP/sBP Treadmill
Study (min)
1 61 M CLI ASO Upper Ulcer, rest pain Ulcer slightly diminished in size,
and rest pain markedly improved.a
þ0.07 þ1.0 (þ6.8%) þ16.0 (þ358.1%) e
2 72 M CLI ASO Lower Ulcer,
bone necrosis
Ulcer healed by good granulation. 0.04 þ38.6 (þ55.1%) 10.0 (32.9%) e
3 36 M CLI TAO Upper Finger gangrene,
rest pain
Gangrene worsened transiently,
but rest pain markedly improved.b
e 27.9 (28.5%) þ5.3 (þ11.4) e
4 51 M CLI TAO Upper Finger gangrene,
rest pain
Gangrene became dry, and rest
pain markedly improved.
e þ88.3 (þ110.2%) 6.0 (16.3%) e
5 39 M CLI TAO Lower Rest pain Rest pain disappeared. e þ48.2 (þ87.1%) 6.3 (þ19.1%) e
6 84F IC ASO Lower IC (200 m) Walking distance improved
to 500 m
at 1 month, but stenotic lesion
newly appeared at another site.
0.15 4.1 (4.2%) e MWT þ0.60,
COT þ0.70
7 67 M IC ASO Lower IC (300 m) IC disappeared at 3 months. 0.07 þ7.2 (þ5.4%) e MWT >þ 11.08,
COT >þ 18.68
8 81F IC ASO Lower IC (100 m) IC markedly improved at
6 months.
0.03 þ27.6 (þ32.6%) e MWT þ5.90,
COT þ7.20
a Case 1 underwent repeated treatment 6 months later. The ulcer had completely healed at 4 years after the first treatment.
b Case 3 suffered transient worsening of gangrene because of infection in the affected finger.
c Pressure index indicates resting ankleebrachial pressure index (ABPI) or the ratio of systolic blood pressure of the affected/
non-affected upper arm. MZmale; FZ female; CLIZ critical limb ischaemia; ICZ intermittent claudication; ASOZ arteriosclerosis
obliterans; TAOZ thromboangiitis obliterans (Buerger’s disease); tcPO2Z transcutaneous oxygen pressure; SPPZ skin perfusion pres-
sure; MWTZmaximum walking time; COTZ claudication onset time.
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74 T. Hashimoto et al.In addition to clinical symptoms, the ischaemic condition
was assessed by various quantitative measurements at
baseline and 1, 3 and 6 months after treatment. First,
resting ankleebrachial pressure index (ABPI) or the ratio of
systolic blood pressure of the affected/non-affected upper
arm was measured in ASO patients. Exercise performance in
patients with claudication was measured with a treadmill
protocol (speed: 2.4 km/h, grade: 12%, time: 20 min
maximum). Limb perfusion was assessed by transcutaneous
PO2 (tcPO2) in patients with CLI and IC, and skin perfusion
pressure (SPP) in patients with CLI. The patients also
underwent digital subtraction angiography at baseline,
1 month and 6 months.
Results
No serious adverse events were observed. A temporal
decrease in blood pressure by about 20 mmHg without
symptoms was observed in two patients. A mild elevation of
creatine kinase was observed in two patients but cleared
spontaneously within a week without any sign of acute
emboli or worsening of ischaemia. Renal abnormalities
were not observed in this series. A low level of bFGF
(<10e24 ng/ml) was detected only on the day of treatment
in some cases. No patient developed proliferative retinop-
athy or malignancy in the follow-up through 1 year.
Regarding clinical symptoms, the ulcer completely
healed in one of four patients with an ulcer or gangrene
(Case 2). The toe ulcer with osteomyelitis had healed 5
months after treatment without concomitant usage of
antibiotics. The patient had no relapse of ulcer at 41
months. The ulcer or gangrene had diminished or become
dry at 6 months in the other three cases, although transient
worsening of gangrene due to infection was experienced in
one case (Case 3). Among them, Case 1 had marked
improvement of cyanosis and pain immediately after
treatment. He received additional treatment for the
residual ulcer 6 months after the first treatment, and finally
achieved healing of the ulcer at 4 years, after persistence
of a warm sensation in the affected hand. The gangrene in
Case 3 with transient worsening became dry at 6 months,
and he had no relapse of rest pain at 3-year follow-up. The
finger gangrene in Case 4 became dry at 6 months the pain
lessened. This case additionally developed gangrene in
a toe one year after treatment of his upper arm, and again
was treated with 100 mg bFGF for the lower limb. He had
improvement of pain at 1 month after the second treat-
ment, but was lost to follow-up thereafter.
Among the four patients with severe rest pain, the
symptom had completely disappeared at 4 months in one
case (Case 5) and markedly improved in the other three
cases. Case 5 had no relapse of rest pain at 26 months’
follow-up.
All three patients with IC showed an increase in maximum
walking time and claudication onset time (Table 1). In Case
7, IC had resolved within 3 months. He had no relapse of
claudication at 1 year post-treatment. Case 6 had improve-
ment in subjective symptoms at 3 months, but developed
stenosis of the common femoral artery in the treated limb at
6 months, necessitating femoropopliteal bypass.
Pressure index measurements of the affected limbs of
ASO patients showed no improvement. TcPO2 in the lowerthigh, foot or hand had improved in six of eight cases at 6
months. On the other hand, SPP in the foot or hand of CLI
patients did not show a consistent change (Table 1).
Generally, no apparent growth of collaterals was visible on
angiography.
No patient required any amputation during the follow-up
period.
Discussion
A priority of the current study was to assess the safety of
this novel delivery system of bFGF in patients with PAD.
bFGF protein itself has an acute vasodilatory effect and the
potential to induce nephropathy.14,15 However, the hypo-
tensive reaction was absent or mild and proteinuria did not
occur with this method. The reason may be that the slow
release of the protein by AGHMs into the circulation miti-
gated the peak serum level of bFGF. In fact, a low level of
bFGF was detected by ELISA only on the day of treatment.
We believe this result indicates relatively high accumula-
tion of administered bFGF in the ischaemic limb, spared
from going into the systemic circulation which may lead to
unfavourable systemic side-effects.
We also recognised some favourable changes by
subjective and objective evaluation in this series. Firstly,
all cases showed improvement in symptoms, although this
was temporary in some patients. In particular, rest pain
improved in all CLI cases. Furthermore, treadmill testing in
all IC cases showed salutary changes. These results are
clinically encouraging, even taking into account the possi-
bility of the influence of a placebo response or the natural
history of the diseases.
On the other hand, the effect did not seem sufficient to
induce complete healing of ulcers or necrosis in CLI. Also,
we did not recognise significant improvement by objective
testing of the ischaemic condition.
Part of this lack of appreciable efficacy may be attrib-
utable to the low dose of administered bFGF, compared to
that in previous clinical trials with multiple doses of 30 mg/
kg bFGF.9,10 Now, we are planning a next-stage trial with
higher doses.
Limitations of our study include the lack of a control group
and the small number of enrolled patients. Another potential
disadvantage is failure to include a preceding period to
observe the improvement by walking training in IC patients.
In conclusion, selective sustained delivery of bFGF by
AGHMs was suggested to be safe and well-tolerated in PAD,
without serious complications or worsening ischaemia.
Initiation of dose escalation trials is warranted.
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